Our primary objective was to investigate complete reporting of harms in systematic reviews (SRs) on CAR-T therapy. Eligible SRs evaluating the effects of CAR-T therapy were identified by performing a search of major databases including MEDLINE (Pubmed and Ovid), EMBASE, Epistemonikos and Cochrane Databases for Systematic Reviews in May 2022. Investigators conducted screening and data extraction in a masked, duplicate fashion. AMSTAR-2 was used to assess the methodological quality of included SRs. Corrected covered area (CCA) was calculated for overlap of primary studies between SR dyads. Inclusion criteria was met for 45 SRs consisting of 929 primary studies. We found 13 SRs reported no harms, and reported less than 50% of harms items. AMSTAR-2 appraised 41 SRs as ‘critically low’(41/45, 91.1%) and 4 SRs as ‘low’ (4/45, 8.9%). A significant association was found between completeness of harms reporting and whether harms were specified as an outcome. No other statistically significant associations were found. Three CCA dyads had a CCA > 50% and were compared to investigate shared or different harms reported. The assessment of harms reporting was found to be insufficient. Because of the importance of SRs in clinical therapy decision-making, it is essential to enhance reporting of harms in every aspect.
|Original language||American English|
|State||Published - 4 Nov 2022|
|Event||111th Annual Technical Meeting, Oklahoma Academy of Science - Oklahoma State University Center for Health Sciences, Tulsa, United States|
Duration: 4 Nov 2022 → 4 Nov 2022
|Conference||111th Annual Technical Meeting, Oklahoma Academy of Science|
|Abbreviated title||OAS Meeting 2022|
|Period||4/11/22 → 4/11/22|